You have reached the HIVandHepatitis.com legacy site. Please visit our new site at hivandhepatitis.com

 Google Custom Search
Bristol-Myers-Squibb Begins Enhanced Co-Pay Assistance for Atazanavir (Reyataz) and Efavirenz (Sustiva)

SUMMARY: Bristol-Myers Squibb recently announced that it was changing its patient assistance programs for its protease inhibitor atazanavir (Reyataz) and NNRTI efavirenz (Sustiva) to eliminate a $50 co-pay. Effective January 1, 2010, the programs will now cover the full cost of private insurance out-of-pocket co-pays up to $200 per month for either drug (the Atripla efavirenz/tenofovir/emtricitabine coformulation is not included). Individuals covered by Medicaid, Medicare, AIDS Drug Assistance Programs (ADAPs), or residing in Massachusetts (which has a universal health insurance program) are not eligible.

By Liz Highleyman

Below is an announcement from Bristol-Myers-Squibb describing the changes to the program.

Enhanced Reyataz and Efavirenz Co-Pay Benefit Program

December 17, 2009 -- We are enhancing the Bristol-Myers Squibb Co-pay Benefit Program beginning on January 1, 2010, for eligible new and existing Reyataz (atazanavir sulfate) and Sustiva (efavirenz) patients who have out-of-pocket costs through their commercial insurance coverage. We recognize that, especially in this economic environment, out-of-pocket costs for HIV medicines may be prohibitive even for patients who have prescription drug benefits. This program reflects Bristol-Myers Squibb's ongoing commitment to helping patients who need our medicines to access them.

The Reyataz and Sustiva Co-pay Benefit Program will allow eligible patients to save up to $200 of co-pay costs monthly, for up to a year. Bristol-Myers Squibb will now cover the first $200 of a patient's monthly co-pay or co-insurance costs; the patient will be responsible for any amount over $200.

To access this benefit, eligible patients need to obtain a Co-pay Benefit Card to take to the pharmacy each time they fill their prescription for Reyataz or Sustiva. Benefit cards are available through their healthcare provider, select pharmacies, or online at www.BMSHIVCoPayProgram.com. Eligible patients who are currently utilizing our Co-pay Benefit Program for Reyataz or Sustiva do not need to obtain new benefit cards. hese patients will begin receiving these new benefits, subject to the new program end date, upon their next use of their Co-pay Benefit Card.

The Co-pay Benefit Card is not valid in Massachusetts or for prescriptions purchased under Medicaid, Medicare, or federal or state programs (including state prescription drug programs, or private indemnity or HMO insurance plans, which reimburse patients for the entire cost of the prescription drugs). First use must take place by December 31, 2010.

This Co-pay Benefit Program is for eligible commercially insured patients only. For patients living with HIV who are uninsured or underinsured, Bristol-Myers Squibb offers other programs to support access to medicines. Bristol-Myers Squibb provides our medicines free of charge to those who qualify through our Access Virology Patient Assistance Program and also participates in the pharmaceutical industry's Together Rx Access Program.

Bristol-Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines that help patients prevail over serious diseases.

1/05/10

Source
Bristol-Myers-Squibb. Enhanced Reyataz Co-Pay Benefit Program. December 17, 2009.

 

 

 

 

 

 

 

 

 

 

 

 

FDA-approved HIV
and AIDS Treatments
Protease Inhibitors PIs
non Nucleoside Reverse
  
Transcriptase Inhibitors nNRTIs
Nucleoside / Nucleotide
  
Reverse Transcriptase Inhibitors NRTIs
Fixed-dose Combinations
Entry / Fusion Inhibitors EIs
Integrase Inhibitors

Experimental Treatments

HIV and AIDS
Articles by Topic
Adverse Events
Opportunistic Infections
Metabolic Complications
Lipodystrophy - Fat Redistribution
Treatment Guidelines
Women/Children